Despite higher risk factors such as portal vein thrombosis being more exposed in the anti-PD1 combination therapy group (Table 1), this treatment indicated significant improvement in both short-term outcomes (ORR, DCR) and long-term outcomes (PFS, OS) compared to monotherapy (Table 1; Fig. 4). This evidence concerns the gene PDCD1 and Portal vein thrombosis.